Aspen Pharmacare Turns Value-Unlock Corner: Net Cash, Sterile-Led Growth, and a Bigger Buyback
After a decade of investment, the specialty-pharma group is harvesting cash, raising steriles guidance, and returning capital.
APN.JO · Earnings Call · 2026-09-03
The Pyramid Returns
At its FY2026 annual results, Aspen Pharmacare laid out a narrative of resilience meeting inflection. Group revenue was flat in constant-exchange-rate terms, but the 'pyramid' did the heavy lifting: normalized EBITDA grew 14% to ZAR7.7 billion, headline earnings per share rose 28% to ZAR8.02, and free cash flow skyrocketed to ZAR3.8 billion from near zero. The company ended the year in a net cash position of ZAR0.8 billion after the ZAR28 billion APAC divestment — and it is already deploying that strength into the market.
"We've got the reins firmly in hand," said CEO Stephen Saad as he handed over to the financials. That confidence crystallizes in the headline he has been building toward for a decade:
I'm glad to say this is the first time I'm going to say this in 25 years. We don't have debt, and we're going to deliver ZAR 9 billion -- over ZAR 9 billion of earnings next year.
Unlocking Value in APAC
The APAC divestment — completed in May — was the year's signature corporate move, generating ZAR28 billion in gross proceeds and crystallizing an 11.5x EBITDA multiple. CFO Sean Capazorio framed it not as a one-off but as a signal of intrinsic worth: "This is an indicator of the underlying asset value of the sum of our parts..." That sum of parts theme recurs as management repeatedly asserts the market does not reflect the business's true worth.
Capital allocation has already shifted accordingly. Beyond a 20% general share-buyback authority, Aspen has now repurchased ZAR2 billion (approximately 3% of shares). Stephen made clear that buybacks are the preferred use of a growing cash pile, especially against the backdrop of what he describes as a value arbitrage between the market capitalization and the sum of the parts.
Sterile Comeback, Now With a Turbocharger
Perhaps the most consequential turnaround is in the Sterile finished dose form. The business lost a ZAR1 billion contract last year, but the reshape program added ZAR1.2 billion EBITDA in FY2026 — more than offsetting the loss. Management was careful to frame this as just the opening chapter: the FY2027 guidance for sterile EBITDA has been raised from ZAR1.7 billion to ZAR2.2 billion.
"We lost ZAR 1 billion of mRNA contract. However, we – through our reshape program in our FDF sterile, we were able to grow that EBITDA by ZAR 1.2 billion," Capazorio noted. Stephen added that the steriles unit will be "the primary driver of group growth" in the coming year, with revenue expected to climb by over 50% off a much lower cost base.
Mounjaro Powers South Africa, GLP-1 Goes Global
The Mounjaro story remains a powerful engine. In South Africa, the GLP-1 market nearly doubled to ZAR2.8 billion, and Mounjaro's share jumped from 15% to 53% — accounting for 40% of all private-market growth. Stephen now expects over ZAR2 billion in Mounjaro sales in FY2027. Beyond South Africa, two semaglutide generic dossiers are pending in Canada, with Brazil advancing and Kenya/Nigeria submitted. Management is deliberately conservative about including GLP-1 upside in guidance, but the optionality is clear.
The competitive environment is acknowledged: "It's going to be a very competitive market," Stephen conceded, but he believes affordability will unlock a far larger patient base. His prior-quarter comments echo that conviction:
“So the GLP-1 situation in South Africa, it's quite interesting and interesting dynamic because we will have a generic semaglutide in the market as well.” — Stephen Saad, Chief Executive Officer (CEO) · 2026-03-04
From ROIC Criticism to Capital Discipline
The market has long criticized Aspen's return on invested capital, and management has heard it. In March, Stephen conceded: "The return on invested capital is not acceptable. I absolutely agree with you." Now, with the APAC divestment and lower capital intensity, the group is positioning ROIC to improve — a theme reinforced by the emphasis on free cash flow and organic growth rather than M&A.
As the company transitions from heavy investment to harvest mode, the tension between its own sum-of-the-parts valuation and the market's view remains a central investment narrative. With net cash, a clearer capital-return framework, and a steriles recovery that is ahead of plan, Aspen appears to be entering a phase where the numbers finally back the talk.